)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
Omeros Corp (OMER) investor relations material
Omeros Corp Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary14 Aug, 2025
Executive summary
Net loss for Q2 2025 was $25.4M ($0.43/share), a significant improvement from $56.0M ($0.97/share) in Q2 2024, mainly due to lower manufacturing expenses and program prioritization.
Cash and investments totaled $28.7M as of June 30, 2025, with an additional $20.6M raised in July via a direct offering at a 14% premium.
Major debt restructuring reduced 2026 Notes from $98M to $17.1M, extended maturities to 2029, and eliminated a $20M prepayment requirement.
Regulatory progress for narsoplimab includes BLA resubmission to FDA (PDUFA date: Dec 26, 2025) and EMA review, with a decision expected mid-2026.
Advanced discussions for a potential multi-billion dollar asset transaction could provide significant upfront cash, repay all term loans and notes, and fund over 12 months of operations.
Financial highlights
Q2 2025 net loss: $25.4M ($0.43/share) vs. $56.0M ($0.97/share) in Q2 2024; six-month net loss: $58.9M ($1.01/share).
Cash and investments: $28.7M as of June 30, 2025; $20.6M raised in July 2025.
Operating expenses dropped to $32.4M in Q2 2025 from $59.2M in Q2 2024, reflecting cost controls and program prioritization.
Net income from discontinued operations (OMIDRIA): $0.5M in Q2 2025, down from $9.1M in Q2 2024.
Interest expense decreased year-over-year due to lower OMIDRIA royalty obligation remeasurement and reduced convertible note balances.
Outlook and guidance
Q3 2025 operating expenses expected to decrease due to paused clinical trials and cost controls.
Interest and other income projected to remain stable; interest expense may rise if no OMIDRIA royalty remeasurement occurs.
Income from discontinued operations expected between $5M and $7M, excluding non-cash adjustments.
Ongoing need to raise additional capital; potential asset/licensing transaction could provide significant upfront and milestone payments.
Preparing for anticipated narsoplimab approval and launch in TA-TMA, with phased onboarding of sales professionals.
Narsoplimab launch vs OMIDRIA: key differences?
Physician comfort level with narsoplimab?
FDA request causing PDUFA delay: details?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Omeros Corp earnings date
Q3 202512 Nov, 2025
Next Omeros Corp earnings date
Q3 202512 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
)
Edge19 Sep 2025
American Express: An Empire of Plastic
How history, brand, and structure have steadily built American Express' moat, and why Warren Buffett still calls it a one-of-a-kind business.
Frequently asked questions
Omeros Corp is a biopharmaceutical company focused on developing and commercializing small-molecule and protein therapeutics. The company's research is centered on treatments for inflammation, immune disorders, and central nervous system conditions. Omeros also explores therapies targeting complement-mediated diseases, aiming to address various unmet medical needs. Its pipeline includes both clinical-stage and preclinical programs, with a focus on advancing innovative therapies that modulate key biological pathways involved in immune and inflammatory responses. The company is headquartered in Seattle, Washington, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage